Skip to Content
Merck
All Photos(1)

Documents

A0365900

Amikacin sulfate

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

Amikacin disulfate salt

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C22H43N5O13 · 2H2SO4
CAS Number:
39831-55-5
Molecular Weight:
781.76
Beilstein:
6172633
MDL number:
MFCD00167475
UNSPSC Code:
41116107
PubChem Substance ID:
329770610
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

amikacin

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

OS(O)(=O)=O.OS(O)(=O)=O.NCC[C@H](O)C(=O)N[C@@H]1C[C@H](N)[C@@H](O[C@H]2O[C@H](CN)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O

InChI

1S/C22H43N5O13.2H2O4S/c23-2-1-8(29)20(36)27-7-3-6(25)18(39-22-16(34)15(33)13(31)9(4-24)37-22)17(35)19(7)40-21-14(32)11(26)12(30)10(5-28)38-21;2*1-5(2,3)4/h6-19,21-22,28-35H,1-5,23-26H2,(H,27,36);2*(H2,1,2,3,4)/t6-,7+,8-,9+,10+,11-,12+,13+,14+,15-,16+,17-,18+,19-,21+,22+;;/m0../s1

InChI key

FXKSEJFHKVNEFI-GCZBSULCSA-N

Looking for similar products? Visit Product Comparison Guide

Related Categories

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Amikacin sulfate EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

Pictograms

Health hazardExclamation mark
GHS08,GHS07

Signal Word

Warning

Hazard Statements

H317,H361fd

Hazard Classifications

Repr. 2 - Skin Sens. 1

Storage Class Code

11 - Combustible Solids

WGK

WGK 2

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Saloni Singla et al.
The Journal of antibiotics, 67(4), 305-309 (2014-01-16)
The purpose of this study was to develop a biofilm model of Klebsiella pneumoniae B5055, mimicking in vivo biofilm system so as to determine susceptibility of different phases of biofilm to antibiotics by three-dimensional analysis. Artificial mature biofilm of K.
Dorota Wrześniok et al.
Toxicology in vitro : an international journal published in association with BIBRA, 27(3), 1102-1108 (2013-02-19)
Amikacin is principally used to treat infections caused by microorganisms resistant to other aminoglycosides. Ototoxicity is one of the side effects of amikacin, but the causative mechanism of damage to the ear has not been fully established. Thus, the aim
F D Pien et al.
American journal of hospital pharmacy, 38(7), 981-989 (1981-07-01)
The antibiotic spectrum, pharmacology, adverse effects, and therapeutic use of amikacin sulfate are reviewed. Amikacin, a semisynthetic analog of kanamycin, is highly active against most gram-negative bacteria including many gentamicin-resistant strains. Amikacin's pharmacologic properties have been studied extensively in both
Anna Belcarz et al.
International journal of pharmaceutics, 454(1), 285-295 (2013-07-16)
Following the quest for new composite materials for bone tissue engineering, a novel elastic hydroxyapatite-glucan composite loaded with two aminoglycoside antibiotics was prepared. The porosity of the composite and the drug release profiles in closed-loop and semi-open systems were tested.
J P Clancy et al.
Thorax, 68(9), 818-825 (2013-06-12)
Arikace is a liposomal amikacin preparation for aerosol delivery with potent Pseudomonas aeruginosa killing and prolonged lung deposition. To examine the safety and efficacy of 28 days of once-daily Arikace in cystic fibrosis (CF) patients chronically infected with P aeruginosa.
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service